Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Rhea-AI Summary

Evaxion (NASDAQ: EVAX) presented new biomarker and immune data for its AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting on November 7, 2025.

Data from the phase 2 trial—conducted in combination with Merck's anti-PD-1 therapy KEYTRUDA—report longitudinal blood sampling that characterized circulating T-cell subsets before, during and after treatment. In analyzed patient subsets, clinical responses were accompanied by a rapid and sustained induction of EVX-01-specific T cells. The release complements previously presented two-year clinical efficacy data from the same trial.

Positive

• Presented new immune biomarker data at SITC 2025 on November 7, 2025
• Observed rapid, sustained induction of EVX-01-specific T cells in analyzed patient subsets

Negative

• None.

• New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting
• Following the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, the new data further adds to EVX-01’s already strong data package

COPENHAGEN, Denmark, November 7, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data exploring immune responses following treatment with AI-designed personalized cancer vaccine EVX-01. The data was presented today in a poster session at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting taking place in National Harbor, Maryland.

Developed with Evaxion’s AI-Immunology™ platform, EVX-01 is designed to target multiple neoantigens - cancer unique proteins arising from mutations - and to induce a clinically relevant immune response. The new biomarker and immune data stems from the phase 2 trial evaluating EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced melanoma (skin cancer).

Longitudinal patient blood samples were collected before, during and after treatment to unravel treatment-induced changes in specific immune cell populations. More specifically, circulating T-cell subsets were characterized aiming at increasing the understanding of the immune responses induced by EVX-01. In subsets of analyzed patients, clinical responses were accompanied by a rapid and sustained induction of EVX-01-specific T-cells.

“We are pleased with the opportunity to present these exploratory translational data at a conference as important as SITC as we continue to add to EVX-01’s strong data package. Having presented the two-year clinical efficacy data from the phase 2 trial just last month at the European Society for Medical Oncology 2025 congress, we are encouraged by the interest in EVX-01 from the medical community”, says Birgitte Rønø, CSO and interim CEO of Evaxion.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

FAQ

What data did Evaxion (EVAX) present at SITC on November 7, 2025?

Evaxion presented new phase 2 biomarker and immune data characterizing circulating T-cell subsets after EVX-01 plus KEYTRUDA treatment.

What immune effect was reported for EVX-01 in the phase 2 trial?

In subsets of analyzed patients, clinical responses were accompanied by a rapid and sustained induction of EVX-01-specific T cells.

Was the EVX-01 data presented in combination with pembrolizumab (KEYTRUDA)?

Yes. The phase 2 trial data reported were from EVX-01 given in combination with Merck's anti-PD-1 therapy KEYTRUDA.

Did Evaxion link the SITC data to prior clinical results for EVX-01?

Yes. The new immune data were described as adding to EVX-01’s data package following previously presented two-year clinical efficacy results.

Where and when was Evaxion's EVX-01 poster presented?

The poster was presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting in National Harbor, Maryland on November 7, 2025.

How were immune responses measured in the EVX-01 phase 2 study?

Longitudinal patient blood samples were collected before, during and after treatment to characterize circulating T-cell subsets and treatment-induced changes.